Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N,N-trimethyl-2-(phosphonooxy)ethanaminium is a small molecule also known as phosphocholine. It is the choline ester of phosphoric acid and serves as an intermediate in the biosynthesis of phosphatidylcholine, a major component of biological membranes. In pharmaceutical contexts, its calcium and magnesium salts have been used therapeutically in hepatobiliary dysfunction. The compound itself is not approved for clinical use but has been investigated in early-phase clinical trials[1][2][8]. Its primary mechanism involves acting as a precursor or metabolite within choline and phospholipid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N,N,N-trimethyl-2-(phosphonooxy)ethanaminium.